A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
Estonia- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to Estonia148 clinical trials in Tallin, Estonia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in EstoniaKliinilisedUuringud.ee(opens in a new tab)
EstoniaOrelabrutinib in Patients with Primary Progressive Multiple Sclerosis
EstoniaLong-Term Safety and Efficacy of Zasocitinib in Adults with Active Psoriatic Arthritis
EstoniaStudy of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.
EstoniaA Study Comparing Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
EstoniaStudy of Zasocitinib and Apremilast for Adults with Active Psoriatic Arthritis Who Have Not Used Biologic Medicines
EstoniaStudy on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History
EstoniaStudy on the Effects of MORF-057 for Adults with Moderate to Severe Crohn's Disease
EstoniaStudy on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis
EstoniaStudy on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation
EstoniaA double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis
EstoniaEfficacy and safety of lunsekimig in adults with inadequately controlled eosinophilic COPD: a randomized, double‑blind, placebo‑controlled trial
EstoniaThe busiest research cities in the country
What the registry says about research in the country
Clinical investigations focusing on innovative treatments for ulcerative colitis, specifically targeting patients with mild to moderate left-sided manifestations of the condition. The research explores new therapeutic approaches using targeted delivery methods.
These trials aim to evaluate the effectiveness of a new localized treatment approach compared to placebo, potentially offering improved options for patients with inflammatory bowel conditions.
Tell us about your condition – we search every trial in Europe and connect you with the right site.